Showing 121-130 of 454 results
Consistent strong performance sees Helsinn Advanced Synthesis SA win six awards for the third consecutive year in Quality, Reliability, Capabilities, Expertise and Compatibility, and the newest category – Development – earning a place among the best in the industry
Data to be presented at ASCO and EHA in June Abstracts now available online
Lugano, Switzerland and Pickering, Canada, June 6, 2017 – Helsinn Group and Purdue Pharma (Canada) today announce that they have signed a distribution and licence agreement granting Purdue Pharma (Canada) exclusive rights to distribute, promote, market and sell ALOXI® (palonosetron hydrochloride) in Canada. ALOXI® is an anti-emetic (5-HT3 receptor antagonist) authorized for sal...
Helsinn returns elsiglutide to Zealand Zealand now has full rights to develop products within cancer-supportive care